Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 30, 2014. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 621,000 Ordinary Shares of 25 pence each.
- Purchase Date: May 30, 2014.
- Price Range: Highest price paid was 1,620.50 pence per share; lowest price paid was 1,601.00 pence per share.
- Treasury Holdings (Settled): 494,090,214 shares (9.23% of total issued share capital).
- Treasury Holdings (Including Unsettled): 495,893,414 shares (10.21% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,856,578,554 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 621,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.21% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Conduct Authority's Disclosure and Transparency Rules regarding share ownership changes.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,856,578,554) to calculate accurate ownership percentages under Disclosure and Transparency Rules.
- Confirm the total Treasury share count (495,893,414 including unsettled) to assess the impact on voting rights.
- Note that the repurchase price range (1,601.00 to 1,620.50 pence) reflects the market price on May 30, 2014.